**Regulatory Submission Document**

**Submission Title:**  
Regulatory Submission Dossier for Phase 2 Clinical Trial of Novostatin (Novitor)

**Protocol Number:** NSP-002-2024  
**Sponsor:** Novitor Pharmaceuticals Inc.  
**Investigational Product:** Novostatin (Trade Name: Novitor)  
**Study Duration:** March 2, 2024 – September 22, 2024  
**Submission Date:** October 10, 2024  
**Regulatory Authority:** U.S. Food and Drug Administration (FDA) / European Medicines Agency (EMA)

**Table of Contents**

1. Cover Letter and Executive Summary
2. Submission Dossier Overview (Common Technical Document Modules)
   * Module 1: Administrative Information
   * Module 2: CTD Summaries
   * Module 3: Quality Information
   * Module 4: Nonclinical Study Reports
   * Module 5: Clinical Study Reports
3. Communications with Regulatory Authorities
   * Pre-Submission Meetings and Correspondence
   * Responses to Agency Queries
4. Summary of Phase 2 Results and Rationale for Phase 3 Advancement
5. Appendices
   * List of Attached Documents
   * Meeting Minutes and Emails
6. Contact Information and Submission Certification

**1. Cover Letter and Executive Summary**

**Cover Letter:**

*October 10, 2024*

Novitor Pharmaceuticals Inc.  
1234 Innovation Drive  
Biotech City, State, Country

Regulatory Affairs Division  
U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Subject: Submission of Phase 2 Clinical Trial Dossier for Novostatin (Novitor) – Protocol NSP-002-2024

Dear Sir/Madam,

We hereby submit the complete dossier for the Phase 2 clinical trial of Novostatin (Novitor), a novel low-dosage statin designed for the management of hypercholesterolemia. The trial, conducted from March 2, 2024, to September 22, 2024, has yielded positive efficacy and safety results, with significant reductions in LDL cholesterol and an improved adverse event profile compared to standard therapies. We respectfully request review of this dossier to support our application for progression to Phase 3 trials.

Enclosed you will find the complete set of documents organized per the Common Technical Document (CTD) structure, including detailed clinical study reports, Investigator’s Brochure, Statistical Analysis Plan, and regulatory communications. We look forward to your feedback and stand ready to provide any additional information as required.

Sincerely,

John Smith, MD  
Director, Regulatory Affairs  
Novitor Pharmaceuticals Inc.  
Email: john.smith@novitorpharma.com  
Phone: (123) 456-7890

**Executive Summary:**

Novostatin (Novitor) is a novel statin agent developed to address high cholesterol with the advantage of low-dosage administration, thereby reducing the incidence of severe side effects. In a Phase 2 randomized, double-blind, placebo-controlled, multi-center trial (NSP-002-2024), 200 patients with hypercholesterolemia were enrolled. The trial demonstrated a statistically significant reduction in LDL cholesterol and favorable safety outcomes, with minimal adverse events reported. Based on these positive outcomes, we propose advancing to Phase 3 clinical trials to confirm efficacy and long-term safety in a broader patient population.

**2. Submission Dossier Overview (CTD Modules)**

**Module 1: Administrative Information**

* **Cover Letter and Application Form**
* **Ethics Committee/IRB Approvals** (see attached document)
* **Informed Consent Forms (ICFs)**
* **Investigator’s Brochure (IB)**
* **Regulatory Correspondence Summary**

**Module 2: CTD Summaries**

* **Overall Summary of Quality, Nonclinical, and Clinical Data**
* **Nonclinical Overview and Summary**
* **Clinical Overview and Summary** (including key efficacy and safety data)

**Module 3: Quality Information**

* **Drug Substance and Drug Product Manufacturing Information**
* **Specifications and Analytical Procedures**
* **Stability Data**
* **Batch Analysis Reports**

**Module 4: Nonclinical Study Reports**

* **Preclinical Pharmacology Data**
* **Toxicology Studies (Acute, Chronic, Safety Pharmacology, Genotoxicity)**
* **Pharmacokinetic Profiles in Animal Models**

**Module 5: Clinical Study Reports**

* **Phase 2 Clinical Study Report**
* **Statistical Analysis Plan (SAP)**
* **Investigator’s Brochure (IB)**
* **Informed Consent Documentation**
* **Monitoring and Data Quality Reports**

**3. Communications with Regulatory Authorities**

**3.1 Pre-Submission Meetings and Correspondence**

* **Pre-IND Meeting (January 2024):**  
  A teleconference was held with FDA representatives to discuss the development plan and Phase 2 trial design. Meeting minutes documented the consensus on study endpoints and safety monitoring.
* **Pre-Submission Email Exchange (February 2024):**  
  A series of emails exchanged with EMA regulators clarified queries regarding dosage rationale and patient safety measures.

**3.2 Responses to Agency Queries**

* **Response to FDA Query (April 2024):**  
  Detailed responses were provided regarding the selection of primary and secondary endpoints, including statistical justification for the sample size.
* **Clarification Request from EMA (May 2024):**  
  Additional data on the preclinical toxicity studies and risk mitigation strategies were submitted in response to an EMA query on the risk/benefit analysis.

All communications are attached as Appendices in this dossier.

**4. Summary of Phase 2 Results and Rationale for Phase 3 Advancement**

The Phase 2 trial of Novostatin (Novitor) demonstrated:

* **Efficacy:**  
  A mean reduction in LDL cholesterol of 18% from baseline compared to a 3% reduction in the placebo group (p<0.001).
* **Safety:**  
  A low incidence of adverse events, with no significant occurrences of liver or muscle toxicity observed.
* **Pharmacokinetics:**  
  Favorable PK profile with dose-proportional plasma concentration increases and a half-life supportive of once-daily dosing.

Based on these robust results, and the demonstration of both clinical efficacy and an improved safety profile at low dosages, we propose the initiation of Phase 3 trials to further validate these findings in a larger, more diverse patient population.

**5. Appendices**

**Appendix A: List of Attached Documents**

* Cover Letter and Executive Summary
* Ethics Committee/IRB Approval Document
* Informed Consent Form (ICF)
* Investigator’s Brochure (IB)
* Statistical Analysis Plan (SAP)
* Complete Phase 2 Clinical Study Report
* Preclinical Study Reports (Module 4)
* Quality Documentation (Module 3)
* Regulatory Correspondence and Meeting Minutes

**Appendix B: Meeting Minutes and Emails**

* Minutes from Pre-IND Meeting (January 2024)
* Email Correspondence with FDA and EMA (February – May 2024)

**6. Contact Information and Submission Certification**

For any further information regarding this submission, please contact:

**Regulatory Affairs Contact:**  
John Smith, MD  
Director, Regulatory Affairs  
Novitor Pharmaceuticals Inc.  
1234 Innovation Drive, Biotech City, State, Country  
Email: john.smith@novitorpharma.com  
Phone: (123) 456-7890

We hereby certify that the information provided in this submission is complete and accurate to the best of our knowledge and that the Phase 2 trial of Novostatin (Novitor) has been conducted in accordance with applicable regulatory standards and guidelines. The positive outcomes from this trial support our intent to advance to Phase 3 clinical development.

John Smith, MD  
Director, Regulatory Affairs  
Novitor Pharmaceuticals Inc.  
Date: October 10, 2024